Off-the-shelf, ready to use advanced therapies with Novel and Innovative proprietary cell lines for drug delivery that increases patients’ care at significantly reduced healthcare cost.
Rius Medical develops drug delivery devices cheaper than the competition so that individuals can afford healthcare. These are off-the-shelf, ready to use advanced therapies with Novel and Innovative proprietary cell lines for drug delivery. Best in class medication that increases patients’ healthcare at significantly reduced healthcare cost. Application in Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes.
Founder and CEO
Almost 10 years of experience in Stem cells culture, Regenerative Medicine, Parkinson’s disease and Leukaemia research. Excellent network in Advanced Therapy Medicinal Products (ATMPs) and health care.
Is it a ridiculous idea to improve care and reduce cost while implementing highly disruptive healthcare technology?
At Rius Medical we see a unique investment opportunity in leading the shift from a mainly clinical focused drug development to a clinical and health economics focused development of therapeutics, key to sustainable healthcare.
You know how healthcare is costing more and more money. Like Biotech and Big pharma bring innovation that cost a fortune to patients. Well what I do is develop drug delivery devices that are cheaper than the competition so that healthcare becomes affordable to individuals no matter what income they make and still we make a profit.
Estimated project cost
EUR 1.4 million
Research, Development & Innovation
Industry for SMEs & Mid-Caps
Partial financing secured
Expected Jobs created
Economic rationale / Business Model
Healthcare cost is shooting up and payers (governments, insurance companies and patients) around the world are increasingly struggling to pay for innovative therapies. Biotech and Big pharma bring innovation that cost a fortune to patients. Well what we do at Rius Medical is develop drug delivery devices that are cheaper than the competition so that healthcare becomes affordable to individuals no matter what income they make and still we make a profit.
Rius Medical re-invents blood transfusion with ready-to-use, off-the-shelf enhanced red blood cells, doing more than simply carry Oxygen as cargo. Through the use of technology and cutting-edge science to accelerate cures for the world’s most life-threatening conditions, we aim to provide solutions for global healthcare’s biggest cost drivers by addressing Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes, all within one platform technology.
Rius Medical mission is to make its highly innovative platform technology available to pharmaceutical and biotech partners to transport their drugs to patients alongside improving lifespan and efficacy while drastically reducing side effects.
Project financing secured: EUR 1.02 million (73 %)
Financing source: Private
Lead Investor Resource Link Consulting Group agreed to a total investment value of 1,000,000 € against 20% ownership as a silent partner to Rius Medical -
[Option 1] Seeking 2x 25,000 € loan (or Convertible Loan at a discounted rate of 0,50 € per share) due to advance fees in the amount of 24,000 € before accessing the 1,000,000 € equity investment to my company… or
[Option 2] Seeking 400,000 € equity against 8% ownership for Project 02 – NK cells as proprietary cell lines for drug delivery.
Existing or potential bottlenecks for the realisation of the project / Potential risks
Red blood cells for drug delivery is Phase III validated in acute lymphoblastic leukemia. Furthermore platform technologies offer lower risk investments, as they bring not only a growing portfolio of candidates, but through out-licensing, support the development of partnership programs. E.g. June 2019 SQZ Biotech and Erytech Pharma partnership to develop red blood cells for drug delivery. Rius Medical targets B2B partnership at 3 years with Erytech Pharma, Rubius Therapeutics and Novo Nordisk.
Project additional information
Rius Medical targets B2B partnerships at 3 years with Erytech Pharma, Rubius Therapeutics and Novo Nordisk if not Servier Laboratories. The partnership deals at 3 year are expected to bring 130 million euro revenue. This is aligned to Rius Medical mission of making its highly innovative platform technology available to pharmaceutical and biotech partners. With a 4 million euro pre-money valuation, Rius Medical is raising Series A funding of up to 1 million euro. An EXIT opportunity at 3 years for early investors investing up to 1 million euro results in 54 million euro financial benefit for FIVE products, if not 10,5 million euro financial benefit for TWO products being transformational improvements on market approved biopharmaceuticals.
The Commission gives no warranty and makes no representation, whether expressed or implied, that the Project Information is error free. The Project Information is provided without any guarantees, conditions or warranties as to its accuracy.
A free translation into English has been provided by the European Commission on this project, for information purposes only. The original language version is the authentic version.